In Regard to Minniti et  al

We read with interest the Oncology Scan feature by Minniti et  al regarding the role of immunotherapy in treatment of melanoma brain metastases.1 Although we agree with the facts articulated by authors' review of the 3 articles, we strongly disagree with the premise that the efficacy of multiagent immunotherapy may obviate the need for stereotactic radiosurge ry (SRS) as an important component of optimal care. Although the 57% 6-month local control rate (with a 26% complete response rate) provided by multiagent immune checkpoint inhibitors (ICI) alone is impressive, these numbers still fall well short of the 87% to 91% 6-month local control rate provided by linear accelerator or GammaKnife SRS.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research